TORONTO / October 21, 2020 / FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced the closing of previously announced definitive agreements with investors for the purchase... read more →
TORONTO / October 16, 2020 / FSD Pharma Inc. (Nasdaq: HUGE) ("FSD Pharma" or the "Company"), today announced that it has entered into definitive agreements with investors for the purchase... read more →
- FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients - TORONTO (September 28, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or the "Company")... read more →
- The study is expected to be conducted at 25-30 hospitals in North America - TORONTO (August 31, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) ("FSD Pharma" or... read more →
TORONTO (July 31, 2020) FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”), today announced that it has entered into definitive agreements with investors for the purchase... read more →
TORONTO (July 13, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (“FSD Pharma” or the “Company”) today announced that it has entered into an Equity Distribution Agreement dated July... read more →
All subjects completed the trial per protocol, no safety concerns found up to the highest dose tested of 2400 mg/day TORONTO (June 22, 2020) – FSD Pharma Inc. (Nasdaq: HUGE)... read more →
TORONTO (June 9, 2020) – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the “Company”) announces the closing of a previously announced private placement of 1,500,000 of the Company’s... read more →
TORONTO / June 4, 2020 / FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”), today announced it has entered into definitive agreements with certain... read more →
TORONTO (June 3, 2020) – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has... read more →